24824-86-0Relevant articles and documents
Nickel-catalyzed deallylation of aryl allyl ethers with hydrosilanes
Ding, Guangni,Fan, Sijie,Wang, Jingyang,Wang, Yu,Wu, Xiaoyu,Xie, Xiaomin,Yang, Liqun,Zhang, Zhaoguo
supporting information, (2021/09/28)
An efficient and mild catalytic deallylation method of aryl allyl ethers is developed, with commercially available Ni(COD)2 as catalyst precursor, simple substituted bipyridine as ligand and air-stable hydrosilanes. The process is compatible with a variety of functional groups and the desired phenol products can be obtained with excellent yields and selectivity. Besides, by detection or isolation of key intermediates, mechanism studies confirm that the deallylation undergoes η3-allylnickel intermediate pathway.
Structure-guided design, synthesis and evaluation of oxazolidinone-based inhibitors of norovirus 3CL protease
Damalanka, Vishnu C.,Kim, Yunjeong,Galasiti Kankanamalage, Anushka C.,Rathnayake, Athri D.,Mehzabeen, Nurjahan,Battaile, Kevin P.,Lovell, Scott,Nguyen, Harry Nhat,Lushington, Gerald H.,Chang, Kyeong-Ok,Groutas, William C.
, p. 881 - 890 (2017/12/26)
Acute nonbacterial gastroenteritis caused by noroviruses constitutes a global public health concern and a significant economic burden. There are currently no small molecule therapeutics or vaccines for the treatment of norovirus infections. A structure-gu
INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP)
-
Page/Page column 143, (2010/06/15)
The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein ("FABP") inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the present invention is shown below: (I)